Advertisement

Supply Chain



Neos Therapeutics on Monday earned Food and Drug Administration approval for its attention-deficit/hyperactivity disorder drug Cotempla.

The U.S. Supreme Court on Monday sided with Bristol-Myers Squibb in a case that could make it more difficult for patients to sue major corporations in state courts over injuries caused by the companies' products, reports Politico.

Advertisement

Most Read

Advertisement
Advertisement